{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:56:36Z","timestamp":1793372196666,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":106,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01712-5","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:15:30Z","timestamp":1781190930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A unimolecular GLP-1 and FGF21 dual agonist for treatment of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1038","volume":"6","author":[{"given":"Parul","family":"Sirohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seh-Hoon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4018-4055","authenticated-orcid":false,"given":"Catherine G.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caslin A.","family":"Gilroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-0961","authenticated-orcid":false,"given":"Rajesh Kumar","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-089X","authenticated-orcid":false,"given":"Anna Mae","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-1836","authenticated-orcid":false,"given":"Ashutosh","family":"Chilkoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"1712_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"1712_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679\u2013690 (2016).","journal-title":"Lancet"},{"key":"1712_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1712_CR4","doi-asserted-by":"crossref","unstructured":"Ravela, N. et al. Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting. Hepatol. Commun. 9, e0670 (2025).","DOI":"10.1097\/HC9.0000000000000670"},{"key":"1712_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.dld.2024.04.021","volume":"56","author":"ML Petroni","year":"2024","unstructured":"Petroni, M. L., Perazza, F. & Marchesini, G. Breakthrough in the treatment of metabolic associated steatotic liver disease: is it all over? Dig. Liver Dis. 56, 1442\u20131451 (2024).","journal-title":"Dig. Liver Dis."},{"key":"1712_CR6","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113\u20131124 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1712_CR7","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1073\/pnas.1214518110","volume":"110","author":"M Amiram","year":"2013","unstructured":"Amiram, M. et al. Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control. Proc. Natl. Acad. Sci. USA 110, 2792\u20132797 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1712_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep31026","volume":"6","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. Sci. Rep. 6, 31026 (2016).","journal-title":"Sci. Rep."},{"key":"1712_CR9","doi-asserted-by":"crossref","unstructured":"Tillman, E. J. & Rolph, T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front. Endocrinol. 11, 601290 (2020).","DOI":"10.3389\/fendo.2020.601290"},{"key":"1712_CR10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison, S. A. et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat. Med. 27, 1262\u20131271 (2021).","journal-title":"Nat. Med."},{"key":"1712_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23, 427\u2013440 (2016).","journal-title":"Cell Metab."},{"key":"1712_CR12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","volume":"37","author":"JP Rose","year":"2025","unstructured":"Rose, J. P. et al. FGF21 reverses MASH through coordinated actions on the CNS and liver. Cell Metab. 37, 1515\u20131529.e6 (2025).","journal-title":"Cell Metab."},{"key":"1712_CR13","doi-asserted-by":"crossref","unstructured":"Liu, C. et al. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. Elife, 12, e83075 (2023).","DOI":"10.7554\/eLife.83075"},{"key":"1712_CR14","doi-asserted-by":"publisher","first-page":"103202","DOI":"10.1016\/j.ebiom.2020.103202","volume":"63","author":"Q Pan","year":"2021","unstructured":"Pan, Q. et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine 63, 103202 (2021).","journal-title":"EBioMedicine"},{"key":"1712_CR15","doi-asserted-by":"publisher","first-page":"eaaz9890","DOI":"10.1126\/sciadv.aaz9890","volume":"6","author":"CA Gilroy","year":"2020","unstructured":"Gilroy, C. A. et al. Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. Sci. Adv. 6, eaaz9890 (2020).","journal-title":"Sci. Adv."},{"key":"1712_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/B978-0-12-416039-2.00024-0","volume":"502","author":"W Hassouneh","year":"2012","unstructured":"Hassouneh, W., MacEwan, S. R. & Chilkoti, A. Fusions of elastin-like polypeptides to pharmaceutical proteins. Methods Enzymol. 502, 215\u2013237 (2012).","journal-title":"Methods Enzymol."},{"key":"1712_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jconrel.2013.07.021","volume":"172","author":"M Amiram","year":"2013","unstructured":"Amiram, M. et al. A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. J. Control Rel. 172, 144\u2013151 (2013).","journal-title":"J. Control Rel."},{"key":"1712_CR18","doi-asserted-by":"crossref","unstructured":"Luginbuhl, K. M. et al. One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer. Nat. Biomed. Eng. 1, 0078 (2017).","DOI":"10.1038\/s41551-017-0078"},{"key":"1712_CR19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/15100","volume":"17","author":"DE Meyer","year":"1999","unstructured":"Meyer, D. E. & Chilkoti, A. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat. Biotechnol. 17, 1112\u20131115 (1999).","journal-title":"Nat. Biotechnol."},{"key":"1712_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jconrel.2018.03.015","volume":"277","author":"CA Gilroy","year":"2018","unstructured":"Gilroy, C. A., Roberts, S. & Chilkoti, A. Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action. J. Control Rel. 277, 154\u2013164 (2018).","journal-title":"J. Control Rel."},{"key":"1712_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","volume":"8","author":"L Hebbard","year":"2011","unstructured":"Hebbard, L. & George, J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 35\u201344 (2011).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1712_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/iep.12008","volume":"94","author":"M Matsumoto","year":"2013","unstructured":"Matsumoto, M. et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int. J. Exp. Pathol. 94, 93\u2013103 (2013).","journal-title":"Int. J. Exp. Pathol."},{"key":"1712_CR23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1021\/bm901387t","volume":"11","author":"JR McDaniel","year":"2010","unstructured":"McDaniel, J. R. et al. Recursive directional ligation by plasmid reconstruction allows rapid and seamless cloning of oligomeric genes. Biomacromolecules 11, 944\u2013952 (2010).","journal-title":"Biomacromolecules"},{"key":"1712_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/978-1-59745-196-3_19","volume":"498","author":"JE Tropea","year":"2009","unstructured":"Tropea, J. E., Cherry, S. & Waugh, D. S. Expression and purification of soluble His(6)-tagged TEV protease. Methods Mol. Biol. 498, 297\u2013307 (2009).","journal-title":"Methods Mol. Biol."},{"key":"1712_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47519-7","volume":"15","author":"NC Tang","year":"2024","unstructured":"Tang, N. C. et al. Synthetic intrinsically disordered protein fusion tags that enhance protein solubility. Nat. Commun. 15, 3727 (2024).","journal-title":"Nat. Commun."},{"key":"1712_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103672","volume":"9","author":"I Ozer","year":"2022","unstructured":"Ozer, I. et al. Polyethylene glycol-like brush polymer conjugate of a protein drug does not induce an antipolymer immune response and has enhanced pharmacokinetics than its polyethylene glycol counterpart. Adv. Sci. 9, e2103672 (2022).","journal-title":"Adv. Sci."},{"key":"1712_CR27","doi-asserted-by":"publisher","unstructured":"Hassouneh, W., T. Christensen, and A. Chilkoti, Elastin-like polypeptides as a purification tag for recombinant proteins. Curr. Protoc. Protein Sci. https:\/\/doi.org\/10.1002\/0471140864.ps0611s61 (2010).","DOI":"10.1002\/0471140864.ps0611s61"},{"key":"1712_CR28","unstructured":"Gilroy, C. A. Controlled Release Systems for Treating Type 2 Diabetes and Their Application toward Multi-Agonist Combination Therapies. Doctoral dissertation (Duke University, 2019)."},{"key":"1712_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/protein\/14.12.993","volume":"14","author":"RB Kapust","year":"2001","unstructured":"Kapust, R. B. et al. Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng. 14, 993\u20131000 (2001).","journal-title":"Protein Eng."},{"key":"1712_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pharmthera.2019.02.005","volume":"198","author":"AM Elmansi","year":"2019","unstructured":"Elmansi, A. M. et al. What doesn\u2019t kill you makes you stranger: dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands. Pharm. Ther. 198, 90\u2013108 (2019).","journal-title":"Pharm. Ther."},{"key":"1712_CR31","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1021\/bm100571j","volume":"11","author":"JA Mackay","year":"2010","unstructured":"Mackay, J. A. et al. Quantitative model of the phase behavior of recombinant pH-responsive elastin-like polypeptides. Biomacromolecules 11, 2873\u20132879 (2010).","journal-title":"Biomacromolecules"},{"key":"1712_CR32","doi-asserted-by":"publisher","first-page":"121985","DOI":"10.1016\/j.biomaterials.2022.121985","volume":"294","author":"I Ozer","year":"2023","unstructured":"Ozer, I. et al. An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug. Biomaterials 294, 121985 (2023).","journal-title":"Biomaterials"},{"key":"1712_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molmet.2012.08.007","volume":"2","author":"AC Adams","year":"2012","unstructured":"Adams, A. C. et al. The breadth of FGF21\u2019s metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2, 31\u201337 (2012).","journal-title":"Mol. Metab."},{"key":"1712_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrendo.2011.77","volume":"7","author":"JG Barrera","year":"2011","unstructured":"Barrera, J. G. et al. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat. Rev. Endocrinol. 7, 507\u2013516 (2011).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1712_CR35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.5551\/jat.RV17025","volume":"25","author":"M Nagao","year":"2018","unstructured":"Nagao, M. et al. Cardioprotective effects of high-density lipoprotein beyond its anti-atherogenic action. J. Atheroscler. Thromb. 25, 985\u2013993 (2018).","journal-title":"J. Atheroscler. Thromb."},{"key":"1712_CR36","doi-asserted-by":"publisher","first-page":"110357","DOI":"10.1016\/j.intimp.2023.110357","volume":"120","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Macrophage in liver fibrosis: identities and mechanisms. Int. Immunopharmacol. 120, 110357 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"1712_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2015.11.012","volume":"290","author":"P Xu","year":"2016","unstructured":"Xu, P. et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-beta\/smad2\/3 and NF-kappaB signaling pathways. Toxicol. Appl. Pharm. 290, 43\u201353 (2016).","journal-title":"Toxicol. Appl. Pharm."},{"key":"1712_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1530\/EC-20-0152","volume":"9","author":"H Keinicke","year":"2020","unstructured":"Keinicke, H. et al. FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation. Endocr. Connect 9, 755\u2013768 (2020).","journal-title":"Endocr. Connect"},{"key":"1712_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama, Y. & Brenner, D. A. Liver inflammation and fibrosis. J. Clin. Invest. 127, 55\u201364 (2017).","journal-title":"J. Clin. Invest."},{"key":"1712_CR40","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/1756283X17725998","volume":"10","author":"SH Cai","year":"2017","unstructured":"Cai, S. H. et al. Increased expression of hepatocyte nuclear factor 4 alpha transcribed by promoter 2 indicates a poor prognosis in hepatocellular carcinoma. Ther. Adv. Gastroenterol. 10, 761\u2013771 (2017).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"1712_CR41","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.ajpath.2024.03.008","volume":"194","author":"M Kotulkar","year":"2024","unstructured":"Kotulkar, M. et al. Role of HNF4alpha-cMyc Interaction in CDE Diet-Induced Liver Injury and Regeneration. Am. J. Pathol. 194, 1218\u20131229 (2024).","journal-title":"Am. J. Pathol."},{"key":"1712_CR42","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/hep.30425","volume":"69","author":"C Unzu","year":"2019","unstructured":"Unzu, C. et al. Pharmacological induction of a progenitor state for the efficient expansion of primary human hepatocytes. Hepatology 69, 2214\u20132231 (2019).","journal-title":"Hepatology"},{"key":"1712_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3727\/105221615X14181438356292","volume":"16","author":"C Walesky","year":"2015","unstructured":"Walesky, C. & Apte, U. Role of hepatocyte nuclear factor 4alpha (HNF4alpha) in cell proliferation and cancer. Gene Expr. 16, 101\u2013108 (2015).","journal-title":"Gene Expr."},{"key":"1712_CR44","doi-asserted-by":"publisher","first-page":"e21286","DOI":"10.1096\/fj.202002203R","volume":"35","author":"CM Williams","year":"2021","unstructured":"Williams, C. M. et al. Monomeric\/dimeric forms of Fgf15\/FGF19 show differential activity in hepatocyte proliferation and metabolic function. FASEB J. 35, e21286 (2021).","journal-title":"FASEB J."},{"key":"1712_CR45","doi-asserted-by":"crossref","unstructured":"Kim, S. J. et al. Regeneration of non-alcoholic fatty liver cells using chimeric FGF21\/HGFR: a novel therapeutic approach. Int. J. Mol. Sci. 25, 3092 (2024).","DOI":"10.3390\/ijms25063092"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01712-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01712-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01712-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:41:49Z","timestamp":1790289709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01712-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01712-5","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.S., S.H.O., A.M.D. and A.C. have submitted invention disclosure for technology titled \u201cA unimolecular GLP1 and FGF21 dual agonist for Non-Alcoholic Steatohepatitis\u201d. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"497"}}